[go: up one dir, main page]

ECSP21080535A - Compuestos y métodos para el tratamiento de covid-19 - Google Patents

Compuestos y métodos para el tratamiento de covid-19

Info

Publication number
ECSP21080535A
ECSP21080535A ECSENADI202180535A ECDI202180535A ECSP21080535A EC SP21080535 A ECSP21080535 A EC SP21080535A EC SENADI202180535 A ECSENADI202180535 A EC SENADI202180535A EC DI202180535 A ECDI202180535 A EC DI202180535A EC SP21080535 A ECSP21080535 A EC SP21080535A
Authority
EC
Ecuador
Prior art keywords
compounds
methods
covid
treatment
cov
Prior art date
Application number
ECSENADI202180535A
Other languages
English (en)
Inventor
Paul Sullivan Bradley
Richard Lillis Jonathan
Louis Hoffman Robert
Louise Hawking Emma
Dimitrova Pencheva Klimentina
Forrest Sammons Matthew
John Thiel Andrew
Rhys Owen Dafydd
Bezawada Padmavani
Youngjin Pettersson Martin
David Ticehurst Martyn
Luthra Suman
Steven Kania Robert
JAINI Rohit
Bryce Tuttle Jamison
Mahadeo Rane Anil
Nathan O'brien Laramy Matthew
Kulkarni Samir
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ECSP21080535A publication Critical patent/ECSP21080535A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C07K5/0823—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp and Pro-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Cephalosporin Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La invención se refiere a compuestos de la fórmula I (Ver gráfico línea 3, pagina 154) I en donde R1, R2 y ----- son como se definen en el presente documento, a composiciones farmacéuticas que comprenden los compuestos y a métodos para el tratamiento de COVID-19 en un paciente mediante la administración de cantidades terapéuticamente eficaces de los compuestos y métodos para la inhibición o prevención de la replicación del SARS-CoV-2 con los compuestos.
ECSENADI202180535A 2020-04-05 2021-11-12 Compuestos y métodos para el tratamiento de covid-19 ECSP21080535A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063005407P 2020-04-05 2020-04-05
US202063038454P 2020-06-12 2020-06-12
US202063061628P 2020-08-05 2020-08-05
US202063065658P 2020-08-14 2020-08-14
US202063073145P 2020-09-01 2020-09-01
US202063114289P 2020-11-16 2020-11-16
US202163163635P 2021-03-19 2021-03-19

Publications (1)

Publication Number Publication Date
ECSP21080535A true ECSP21080535A (es) 2022-03-31

Family

ID=75478095

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202180535A ECSP21080535A (es) 2020-04-05 2021-11-12 Compuestos y métodos para el tratamiento de covid-19

Country Status (19)

Country Link
US (1) US11926642B2 (es)
EP (1) EP3953361A1 (es)
JP (1) JP2023519035A (es)
KR (1) KR20210151949A (es)
CN (1) CN114641485A (es)
AU (1) AU2021253796B2 (es)
BR (1) BR112021022778A2 (es)
CA (1) CA3140164A1 (es)
CO (1) CO2021015318A2 (es)
CR (1) CR20210563A (es)
EC (1) ECSP21080535A (es)
IL (1) IL288061A (es)
MX (1) MX2021013934A (es)
PE (1) PE20220765A1 (es)
PH (1) PH12021552872A1 (es)
TW (1) TWI807291B (es)
UY (1) UY39149A (es)
WO (1) WO2021205298A1 (es)
ZA (1) ZA202109010B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL296522A (en) * 2020-03-20 2022-11-01 Abivax Compounds for treating or preventing a coronaviridae infection and methods and uses for assessing the occurrence of a coronaviridae infection
US11124497B1 (en) 2020-04-17 2021-09-21 Pardes Biosciences, Inc. Inhibitors of cysteine proteases and methods of use thereof
US11174231B1 (en) 2020-06-09 2021-11-16 Pardes Biosciences, Inc. Inhibitors of cysteine proteases and methods of use thereof
US11351149B2 (en) * 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
WO2022133588A1 (en) * 2020-12-21 2022-06-30 The Governors Of The University Of Alberta Rna virus inhibitor compounds and uses thereof
US20240131046A1 (en) * 2021-01-20 2024-04-25 National University Corporation Hokkaido University Anti-viral agent
US12527762B2 (en) 2021-01-28 2026-01-20 Imdpharm Inc. Cocrystal comprising camostat and niclosamide, pharmaceutical composition comprising same and preparation method therefor
RS66997B1 (sr) 2021-04-14 2025-08-29 Shionogi & Co Derivati triazina koji imaju inhibitorno delovanje na replikaciju virusa i farmaceutska kompozicija koja sadrži iste
WO2022266363A1 (en) * 2021-06-16 2022-12-22 The Scripps Research Institute Protease inhibitors for the treatment of coronavirus infections
EP4410292A4 (en) 2021-09-28 2025-09-03 Shionogi & Co PHARMACEUTICAL COMPOSITION CONTAINING A TRIAZINE DERIVATIVE
WO2023054292A1 (ja) 2021-09-28 2023-04-06 塩野義製薬株式会社 トリアジン誘導体を含有する医薬組成物
WO2023027198A1 (ja) 2021-11-24 2023-03-02 塩野義製薬株式会社 トリアジン誘導体を含有する経口投与する製剤
WO2023095860A1 (ja) * 2021-11-26 2023-06-01 塩野義製薬株式会社 ３ｃｌプロテアーゼ阻害剤及びｃｏｖｉｄ－１９治療用薬剤を組み合わせることを特徴とするｃｏｖｉｄ－１９治療用医薬
KR20230140401A (ko) * 2022-03-25 2023-10-06 주식회사 미토이뮨테라퓨틱스 항바이러스용 약학적 조성물 및 이의 용도
WO2023196412A1 (en) * 2022-04-06 2023-10-12 Nobias Therapeutics, Inc. Liquid formulations comprising mitogen-activated protein kinase kinase (mek) inhibitors and methods using same
IL315710A (en) 2022-04-08 2024-11-01 Shionogi & Co The history of Uracil with viral growth inhibitory activity and a pharmaceutical preparation containing it
CN114773405B (zh) * 2022-06-21 2022-09-23 和鼎（南京）医药技术有限公司 一种莫那比拉韦的制备方法
CN115054593B (zh) * 2022-07-15 2023-02-03 深圳市人民医院 防治新型冠状病毒肺炎或检测新冠病毒及突变株的药物及应用
WO2024089159A1 (en) 2022-10-27 2024-05-02 Ubiq Holding B.V. Main protease inhibitors
CN115785080B (zh) * 2022-12-16 2024-10-11 陕西盘龙药业集团股份有限公司 一种尿嘧啶母核类化合物及其制备方法和应用
TW202523309A (zh) * 2023-10-05 2025-06-16 日商塩野義製藥股份有限公司 含有尿嘧啶衍生物之醫藥組合物
WO2025005305A1 (ja) * 2023-10-05 2025-01-02 塩野義製薬株式会社 ウラシル誘導体を含有する製剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1687020A1 (en) 2003-11-20 2006-08-09 Novo Nordisk Health Care AG Therapeutic use of factor xi
WO2005113580A1 (en) 2004-05-21 2005-12-01 Pfizer Inc. Anticoronviral compounds and compositions, their pharmaceutical uses and materials for their synthesis
WO2006061714A2 (en) 2004-12-09 2006-06-15 Pfizer Inc. Anticoronaviral compounds and compositions, their pharmaceutical uses and materials for their synthesis
KR101685941B1 (ko) 2009-07-07 2016-12-13 베링거 인겔하임 인터내셔날 게엠베하 Ｃ형 간염 바이러스 프로테아제 억제제를 위한 약제학적 조성물
PT3077397T (pt) * 2013-12-06 2020-01-22 Vertex Pharma Composto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1,5-a]pirimidin-3-carboxamida útil como inibidor da atr quinase, a sua preparação, diferentes formas sólidas e derivados radiomarcados do mesmo
EP3139920A4 (en) 2014-05-09 2017-11-01 Kineta, Inc. Anti-viral compounds, pharmaceutical compositions, and methods of use thereof
MX2019005202A (es) 2016-11-02 2019-10-14 Centrexion Therapeutics Corp Formulaciones inyectables de capsaicina acuosa estable y usos medicos de los mismos.
US10316021B2 (en) * 2016-11-28 2019-06-11 Pfizer Inc. Heteroarylphenoxy benzamide kappa opioid ligands

Also Published As

Publication number Publication date
US11926642B2 (en) 2024-03-12
MX2021013934A (es) 2021-12-15
PE20220765A1 (es) 2022-05-16
BR112021022778A2 (pt) 2022-11-22
IL288061A (en) 2022-01-01
CR20210563A (es) 2022-01-24
EP3953361A1 (en) 2022-02-16
CA3140164A1 (en) 2021-10-14
WO2021205298A1 (en) 2021-10-14
TW202202148A (zh) 2022-01-16
KR20210151949A (ko) 2021-12-14
AU2021253796B2 (en) 2023-06-01
PH12021552872A1 (en) 2022-03-21
UY39149A (es) 2021-10-29
CN114641485A (zh) 2022-06-17
TWI807291B (zh) 2023-07-01
ZA202109010B (en) 2023-09-27
AU2021253796A1 (en) 2021-12-09
CO2021015318A2 (es) 2021-11-19
US20220017548A1 (en) 2022-01-20
JP2023519035A (ja) 2023-05-10

Similar Documents

Publication Publication Date Title
ECSP21080535A (es) Compuestos y métodos para el tratamiento de covid-19
ECSP21080528A (es) Compuestos antivirales que contienen nitrilo
BR112019024831A2 (pt) composto, sal, solvato ou pró-droga, composição farmacêutica, método de tratamento ou prevenção de uma doença, método para inibir o nlrp3
MX2017014584A (es) Inhibidores heterociclicos de erk1 y erk2 y su uso en el tratamiento del cancer.
CL2023000289A1 (es) Combinaciones para el tratamiento de cáncer
CO2019007409A2 (es) Derivados de la pirimidin enona tricíclica para la inhibición de rorγ y otros usos
ECSP088762A (es) Tratamiento del dolor
MX2021005240A (es) Combinacion de inhibidores de peque?as moleculas cd-47 con otros agentes anticancer.
BR112023025916A2 (pt) Combinação de um inibidor de braf e um inibidor de mek, uso de uma combinação, método para o tratamento ou profilaxia de câncer, composições farmacêuticas e invenção
CL2021001388A1 (es) Compuestos útiles en la terapia para el vih
CL2021000329A1 (es) Compuestos útiles en terapia del vih
MX2021015770A (es) Inhibidores macrociclicos de mcl-1.
MX389553B (es) Composicion para incrementar la expresion de pgc-1alfa
CO2023016136A2 (es) Composiciones y métodos para inhibir la expresión del componente 1 de reducción de amidoxima mitocondrial (marc1)
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
CL2022000781A1 (es) Tratamientos cognitivos medicinales
MX2021013901A (es) Composiciones y métodos para el tratamiento del cáncer.
MX2024007929A (es) Tetrahidropirazolopirimidinas y analogos relacionados para la inhibicion de yap/taz-tead.
ECSP22040362A (es) Derivados de 1,2,4–oxadiazol como agonistas del receptor hepático x
MX2019006940A (es) Uso de compuestos de carbamato para prevencion, alivio o tratamiento del trastorno bipolar.
BR112021019589A2 (pt) Derivados de isocromenos como inibidores de fosfoinositídeo 3-cinases
CL2022001935A1 (es) Compuestos antivirales que contienen nitrilo
UY39738A (es) Compuestos antivirales que contienen nitrilo
AR133541A1 (es) Nuevos compuestos y sus usos
MX2024004483A (es) Compuestos para el tratamiento de sepsis.